Turn Therapeutics Inc. (TTRX)
NASDAQ: TTRX · Real-Time Price · USD
10.41
+0.80 (8.32%)
At close: Aug 7, 2026, 4:00 PM EDT
10.42
+0.01 (0.10%)
After-hours: Aug 7, 2026, 6:29 PM EDT
Turn Therapeutics Employees
Turn Therapeutics had 2 employees as of December 31, 2025. The number of employees decreased by 2 or -50.00% compared to the previous year.
Employees
2
Change
-2
Growth
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,918,253
Market Cap
310.09M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 2 | - | - | 2 | 0 |
| Jun 30, 2025 | 2 | -2 | -50.00% | 2 | 0 |
| Jun 30, 2024 | 4 | - | - | 1 | 3 |
| Dec 31, 2023 | 4 | - | - | 1 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Fate Therapeutics | 161 |
| Zentalis Pharmaceuticals | 106 |
| Neumora Therapeutics | 92 |
| SAB Biotherapeutics | 86 |
| Agenus | 81 |
| Immuneering | 55 |
| Surrozen | 44 |
TTRX News
- 10 days ago - Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026 - Business Wire
- 11 days ago - Turn Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Turn Therapeutics Transcript: Study update - Transcripts
- 4 weeks ago - Turn Therapeutics Press release: Study update - Filings
- 4 weeks ago - Turn Therapeutics Slides: Study update - Filings
- 4 weeks ago - Turn Therapeutics announces final Stage 2 design of atopic dermatitis program - TheFly
- 4 weeks ago - Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - Business Wire
- 4 weeks ago - Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - Business Wire